Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study.

Salmon SE, Haut A, Bonnet JD, Amare M, Weick JK, Durie BG, Dixon DO.

J Clin Oncol. 1983 Aug;1(8):453-61.

PMID:
6366141
2.

Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.

Durie BG, Dixon DO, Carter S, Stephens R, Rivkin S, Bonnet J, Salmon SE, Dabich L, Files JC, Costanzi JJ.

J Clin Oncol. 1986 Aug;4(8):1227-37.

PMID:
3525768
3.

Chemotherapy for multiple myeloma.

Alexanian R, Dreicer R.

Cancer. 1984 Feb 1;53(3):583-8.

4.

Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.

Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B.

J Clin Oncol. 1994 Nov;12(11):2405-14.

PMID:
7964957
5.

Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.

Salmon SE, Tesh D, Crowley J, Saeed S, Finley P, Milder MS, Hutchins LF, Coltman CA Jr, Bonnet JD, Cheson B, et al.

J Clin Oncol. 1990 Sep;8(9):1575-84.

PMID:
2131793
6.

Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.

Bladé J, San Miguel JF, Alcalá A, Maldonado J, Sanz MA, García-Conde J, Moro MJ, Alonso C, Besalduch J, Zubizarreta A, et al.

J Clin Oncol. 1993 Jun;11(6):1165-71.

PMID:
8501503
7.

Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients.

Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD, Mills GM, Barlogie B, Salmon SE.

Blood. 2002 May 1;99(9):3163-8.

8.
9.

Multiple myeloma in central Norway 1981-1982: a randomized clinical trial of 5-drug combination therapy versus standard therapy.

Kildahl-Andersen O, Bjark P, Bondevik A, Bull O, Dehli O, Kvambe V, Nordahl E, Ytrehus K, Lamvik J.

Scand J Haematol. 1986 Sep;37(3):243-8.

PMID:
3538367
10.

Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.

Cavo M, Benni M, Ronconi S, Fiacchini M, Gozzetti A, Zamagni E, Cellini C, Tosi P, Baccarani M, Tura S; Writing Committee of the "Bologna 90" Clinical Trial..

Haematologica. 2002 Sep;87(9):934-42.

11.

Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCS.

Osterborg A, Ahre A, Björkholm M, Björeman M, Brenning G, Gahrton G, Gyllenhammar H, Johansson B, Juliusson G, Järnmark M, et al.

Eur J Haematol. 1989 Jul;43(1):54-62.

PMID:
2670605
12.

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.

Mateos MV, Oriol A, Martínez-López J, Gutiérrez N, Teruel AI, de Paz R, García-Laraña J, Bengoechea E, Martín A, Mediavilla JD, Palomera L, de Arriba F, González Y, Hernández JM, Sureda A, Bello JL, Bargay J, Peñalver FJ, Ribera JM, Martín-Mateos ML, García-Sanz R, Cibeira MT, Ramos ML, Vidriales MB, Paiva B, Montalbán MA, Lahuerta JJ, Bladé J, Miguel JF.

Lancet Oncol. 2010 Oct;11(10):934-41. doi: 10.1016/S1470-2045(10)70187-X. Epub 2010 Aug 23.

PMID:
20739218
13.

Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group.

Zervas K, Pouli A, Perifanis V, Papanastasiou K, Chatziyianni M, Mitsouli C, Maniatis A.

Eur J Haematol. 1996 Aug;57(2):142-8.

PMID:
8856091
14.

Multiple myeloma in central and northern Norway 1981-1982: a follow-up study of a randomized clinical trial of 5-drug combination therapy versus standard therapy.

Kildahl-Andersen O, Bjark P, Bondevik A, Bull O, Burgess G, Dehli O, Hoel S, Jaeger S, Kvambe V, Mürer F, et al.

Eur J Haematol. 1988 Jul;41(1):47-51.

PMID:
3042453
15.

A randomized multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma.

Bladé J, San Miguel J, Alcalá A, Maldonado J, García-Conde J, Moro MJ, Sanz Sanz MA, Alonso C, Zubizarreta A, Besses C, et al.

Blut. 1990 Jun;60(6):319-22.

PMID:
2198075
16.

Treatment of multiple myeloma: a randomized study of three different regimens.

Tribalto M, Amadori S, Cantonetti M, Franchi A, Papa G, Pileri A, Boccadoro M, Dammacco F, Vacca A, Centurioni R, et al.

Leuk Res. 1985;9(8):1043-9.

PMID:
3900591
17.

[Chemotherapy and immunomodulating treatment of patients with multiple myeloma].

Kraj M, Dmoszyńska A, Maj S, Kowalewski J, Rostkowska J, Pogłód R, Sokołowska B, Mendek-Czajkowska E, Kurowska M, Sokołowska U, et al.

Acta Haematol Pol. 1991;22(1):4-20. Polish.

PMID:
1823965
18.

Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients.

Bladé J, San Miguel JF, Fontanillas M, Esteve J, Maldonado J, Alcalá A, Brunet S, García-Conde J, Besalduch J, Moro MJ, Fernández-Calvo J, Conde E, Font L, Gardella S, Carnero M, Carbonell F, Martí JM, Hernández-Martín J, Ortega F, Besses C, Ribera JM, Trujillo J, Escudero ML, Rozman C, Estapé J, Montserrat E.

Hematol J. 2001;2(4):272-8.

PMID:
11920260
20.

Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study.

Salmon SE, Crowley JJ, Balcerzak SP, Roach RW, Taylor SA, Rivkin SE, Samlowski W.

J Clin Oncol. 1998 Mar;16(3):890-6.

PMID:
9508170

Supplemental Content

Support Center